Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Oyster Point Pharma enrolls first subject in OLYMPIA Phase 2 trial » 07:04
06/21/21
06/21
07:04
06/21/21
07:04
OYST

Oyster Point Pharma

$20.16 /

+0.95 (+4.95%)

Oyster Point Pharma…

Oyster Point Pharma announced enrollment of the first subject in the OLYMPIA Phase 2 clinical trial of OC-01 nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy. The OLYMPIA Phase 2 study is a multicenter, randomized, double-masked, placebo-controlled clinical trial to evaluate the safety and efficacy of OC-01 nasal spray in subjects with Mackie's Classification Stage 1 Neurotrophic Keratopathy. The study is expected to enroll approximately 100 subjects at approximately 18 U.S. sites. In this clinical trial, OC-01 nasal spray will be administered three times a day, as compared to placebo nasal spray. The pre-specified primary endpoint of the trial will be the percentage of subjects who achieve complete resolution of fluorescein corneal staining at Day 56.

ShowHide Related Items >><<
OYST Oyster Point Pharma
$20.16 /

+0.95 (+4.95%)

OYST Oyster Point Pharma
$20.16 /

+0.95 (+4.95%)

04/23/21 Piper Sandler
Oyster Point has 'most compelling 'dry eye data to date, says Piper Sandler
08/05/20 Piper Sandler
Oyster Point Pharma remains 'fundamentally undervalued,' says Piper Sandler
OYST Oyster Point Pharma
$20.16 /

+0.95 (+4.95%)

Over a week ago
Hot Stocks
Oyster Point, Adaptive Phage collaborate to target ophthalmic diseases » 07:02
06/10/21
06/10
07:02
06/10/21
07:02
OYST

Oyster Point Pharma

$18.24 /

+0.19 (+1.05%)

Oyster Point Pharma…

Oyster Point Pharma announced a newly formed research collaboration with Adaptive Phage Therapeutics to leverage APT's PhageBank technology for the development of potential treatments for multiple ophthalmic diseases. APT's PhageBank technology is engineered as an ever-expanding library of bactericidal agents, called bacteriophages, to provide broad spectrum coverage. Phages, also are viruses found in the natural environment that infect and replicate specifically in bacteria. Once a bacteriophage attaches to a susceptible bacterium it causes the host cell to die, releasing new bacteriophage to infect other bacteria. APT's approach provides expanded bacterial coverage where prior, traditional, antibiotic approaches have diminished coverage or have become obsolete due to emerging antimicrobial resistance. Under the terms of the collaboration agreement, Oyster Point Pharma has the option and certain rights to obtain an exclusive license to develop and commercialize APT's PhageBank(TM) technology for ophthalmic diseases or disorders. Under the license terms, if such option is exercised, Oyster Point Pharma has agreed to pay APT potential development and regulatory milestones, as well as the potential for sales-related milestones and tiered royalties of net sales, if a licensed phage therapy is approved by the U.S. Food and Drug Administration. APT retains production rights to PhageBank and will supply Oyster Point Pharma product at an agreed upon cost-plus model.

ShowHide Related Items >><<
OYST Oyster Point Pharma
$18.24 /

+0.19 (+1.05%)

OYST Oyster Point Pharma
$18.24 /

+0.19 (+1.05%)

04/23/21 Piper Sandler
Oyster Point has 'most compelling 'dry eye data to date, says Piper Sandler
08/05/20 Piper Sandler
Oyster Point Pharma remains 'fundamentally undervalued,' says Piper Sandler
OYST Oyster Point Pharma
$18.24 /

+0.19 (+1.05%)

Hot Stocks
Oyster Point Pharma announces preclincial study results, pipeline expansion » 08:17
06/03/21
06/03
08:17
06/03/21
08:17
OYST

Oyster Point Pharma

$17.98 /

+0.01 (+0.06%)

Oyster Point Pharma…

Oyster Point Pharma announced the expansion of its pipeline with the introduction of Enriched Tear Film Gene Therapy and proof-of-concept in vivo study results from its first gene therapy candidate, OC-101. ETF Gene Therapy is a proprietary adeno-associated virus based gene therapy approach where a target gene is delivered to human lacrimal gland cells via intralacrimal gland injection. Rather than replacing a gene that is defective or missing, a new target gene is delivered that may potentially produce a selected naturally occurring protein, enzyme, or other therapeutic gene product. The goal for this target gene is to produce a selected gene product to change cell behavior and function on the ocular surface. Oyster Point's investigational drug, OC-01 nasal spray, a highly selective cholinergic agonist, may play a role in ocular surface diseases treated with ETF Gene Therapy through its potential to modulate the secretion of a selected gene product. In this proof-of-concept in vivo study evaluating OC-101, a single, intralacrimal gland injection of an AAV containing the human NGF gene resulted in statistically significant levels of hNGF protein being expressed within the lacrimal gland and tear film of a rabbit model, as compared to control. hNGF was secreted into the tear film as early as Day 7, after the intralacrimal gland injection. No control animals showed evidence of hNGF in the lacrimal gland or tear film. Additionally, three weeks following OC-101 transduction of the lacrimal gland, cholinergic activation of the lacrimal gland with OC-01 nasal spray resulted in statistically significant increases in hNGF expression in the tear film, as compared to pre-cholinergic stimulation levels and as compared to control. After cessation of OC-01 nasal spray, hNGF tear protein levels returned to pre-cholinergic activation levels. During the 42-day study, there were no macroscopic or microscopic safety findings observed associated with the intralacrimal gland administration of OC-101 or OC-01 nasal spray.

ShowHide Related Items >><<
OYST Oyster Point Pharma
$17.98 /

+0.01 (+0.06%)

OYST Oyster Point Pharma
$17.98 /

+0.01 (+0.06%)

04/23/21 Piper Sandler
Oyster Point has 'most compelling 'dry eye data to date, says Piper Sandler
08/05/20 Piper Sandler
Oyster Point Pharma remains 'fundamentally undervalued,' says Piper Sandler
OYST Oyster Point Pharma
$17.98 /

+0.01 (+0.06%)

Over a month ago
Conference/Events
Oyster Point Pharma management to meet virtually with Piper Sandler » 04:55
05/17/21
05/17
04:55
05/17/21
04:55
OYST

Oyster Point Pharma

$16.30 /

+0.005 (+0.03%)

Virtual Meeting to be…

Virtual Meeting to be held on May 17 hosted by Piper Sandler.

ShowHide Related Items >><<
OYST Oyster Point Pharma
$16.30 /

+0.005 (+0.03%)

OYST Oyster Point Pharma
$16.30 /

+0.005 (+0.03%)

04/23/21 Piper Sandler
Oyster Point has 'most compelling 'dry eye data to date, says Piper Sandler
08/05/20 Piper Sandler
Oyster Point Pharma remains 'fundamentally undervalued,' says Piper Sandler
OYST Oyster Point Pharma
$16.30 /

+0.005 (+0.03%)

Conference/Events
Oyster Point Pharma management to meet virtually with Piper Sandler » 10:56
05/14/21
05/14
10:56
05/14/21
10:56
OYST

Oyster Point Pharma

$16.50 /

+0.205 (+1.26%)

Virtual Meeting to be…

Virtual Meeting to be held on May 17 hosted by Piper Sandler.

ShowHide Related Items >><<
OYST Oyster Point Pharma
$16.50 /

+0.205 (+1.26%)

OYST Oyster Point Pharma
$16.50 /

+0.205 (+1.26%)

04/23/21 Piper Sandler
Oyster Point has 'most compelling 'dry eye data to date, says Piper Sandler
08/05/20 Piper Sandler
Oyster Point Pharma remains 'fundamentally undervalued,' says Piper Sandler
OYST Oyster Point Pharma
$16.50 /

+0.205 (+1.26%)

  • 15
    May
Recommendations
Oyster Point has 'most compelling 'dry eye data to date, says Piper Sandler » 04:47
04/23/21
04/23
04:47
04/23/21
04:47
OYST

Oyster Point Pharma

$20.76 /

+0.91 (+4.58%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro reiterates an Overweight rating on Oyster Point Pharma with a $60 price target after taking over coverage of the name saying OC-01 as has generated the "most compelling dry eye data set to date." The analyst anticipates approval by its October 17 FDA action data and believes OC-01's clinical profile "could be disruptive" to the dry eye market based on its rapid onset of action and ability to drive clinical benefit to a greater proportion of patients relative to current standard of care. With those standard of care agents having generated nearly $1.5B in U.S. sales in 2020, OC-01 is well positioned to capture a "significant portion of this opportunity," Catanzaro tells investors in a research note.

ShowHide Related Items >><<
OYST Oyster Point Pharma
$20.76 /

+0.91 (+4.58%)

OYST Oyster Point Pharma
$20.76 /

+0.91 (+4.58%)

08/05/20 Piper Sandler
Oyster Point Pharma remains 'fundamentally undervalued,' says Piper Sandler
05/13/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Kala after 'underwhelming' competitor data
05/11/20 Piper Sandler
Piper says Oyster Point 'highly likely' to get dry eye approval, superior label
OYST Oyster Point Pharma
$20.76 /

+0.91 (+4.58%)

  • 15
    May
Conference/Events
Oyster Point Pharma participates in a conference call with JPMorgan » 12:25
04/05/21
04/05
12:25
04/05/21
12:25
OYST

Oyster Point Pharma

$20.27 /

+1.71 (+9.21%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Rama holds a conference call with President & CEO Nau on April 5 at 1 pm hosted by JPMorgan.

ShowHide Related Items >><<
OYST Oyster Point Pharma
$20.27 /

+1.71 (+9.21%)

OYST Oyster Point Pharma
$20.27 /

+1.71 (+9.21%)

08/05/20 Piper Sandler
Oyster Point Pharma remains 'fundamentally undervalued,' says Piper Sandler
05/13/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Kala after 'underwhelming' competitor data
05/11/20 Piper Sandler
Piper says Oyster Point 'highly likely' to get dry eye approval, superior label
OYST Oyster Point Pharma
$20.27 /

+1.71 (+9.21%)

  • 15
    May
Conference/Events
Oyster Point Pharma participates in a conference call with JPMorgan » 09:27
04/05/21
04/05
09:27
04/05/21
09:27
OYST

Oyster Point Pharma

$18.60 /

+0.25 (+1.36%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Rama holds a conference call with President & CEO Nau on April 5 at 1 pm hosted by JPMorgan.

ShowHide Related Items >><<
OYST Oyster Point Pharma
$18.60 /

+0.25 (+1.36%)

OYST Oyster Point Pharma
$18.60 /

+0.25 (+1.36%)

08/05/20 Piper Sandler
Oyster Point Pharma remains 'fundamentally undervalued,' says Piper Sandler
05/13/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Kala after 'underwhelming' competitor data
05/11/20 Piper Sandler
Piper says Oyster Point 'highly likely' to get dry eye approval, superior label
OYST Oyster Point Pharma
$18.60 /

+0.25 (+1.36%)

  • 15
    May
Over a quarter ago
Hot Stocks
Oyster Point Pharma says FDA accepts NDA for OC-01 (varenicline) nasal spray » 06:06
03/02/21
03/02
06:06
03/02/21
06:06
OYST

Oyster Point Pharma

$19.76 /

-0.07 (-0.35%)

Oyster Point Pharma…

Oyster Point Pharma announced that the U.S. FDA has accepted its New Drug Application for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The Prescription Drug User Fee Act target action date for OC-01 (varenicline) nasal spray is October 17, 2021. At present, FDA has stated that it does not intend to hold an advisory committee meeting to discuss this application.

ShowHide Related Items >><<
OYST Oyster Point Pharma
$19.76 /

-0.07 (-0.35%)

OYST Oyster Point Pharma
$19.76 /

-0.07 (-0.35%)

08/05/20 Piper Sandler
Oyster Point Pharma remains 'fundamentally undervalued,' says Piper Sandler
05/13/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Kala after 'underwhelming' competitor data
05/11/20 Piper Sandler
Piper says Oyster Point 'highly likely' to get dry eye approval, superior label
03/30/20 Piper Sandler
Oyster Point ONSET-2 trial barely impacted by COVID-19, says Piper Sandler
OYST Oyster Point Pharma
$19.76 /

-0.07 (-0.35%)

  • 15
    May
Earnings
Oyster Point Pharma reports Q4 EPS (86c), consensus (79c) » 16:07
02/18/21
02/18
16:07
02/18/21
16:07
OYST

Oyster Point Pharma

$25.76 /

+0.67 (+2.67%)

As of December 31, cash…

As of December 31, cash and cash equivalents were $192.6M, compared to $139.1M as of December 31, 2019. The increase in cash and cash equivalents in the amount of $"The submission of our NDA to the FDA for OC-01 (varenicline) nasal spray represents an important milestone for Oyster Point Pharma and progresses the development of what we believe will be an important first in class nasal spray for the treatment of the signs and symptoms of dry eye disease." said Jeffrey Nau, Ph.D., MMS president and chief executive officer of Oyster Point Pharma. Dr. Nau continued, "We believe that the strength of our clinical data in mild, moderate and severe dry eye patients, and OC-01's novel mechanism of action as shown in pre-clinical and clinical studies to stimulate natural tear film production and re-establish tear film homeostasis, will support eye care practitioners' use of a new tool in their dry eye disease treatment armamentarium, if approved by the FDA."

ShowHide Related Items >><<
OYST Oyster Point Pharma
$25.76 /

+0.67 (+2.67%)

OYST Oyster Point Pharma
$25.76 /

+0.67 (+2.67%)

08/05/20 Piper Sandler
Oyster Point Pharma remains 'fundamentally undervalued,' says Piper Sandler
05/13/20 H.C. Wainwright
H.C. Wainwright reiterates Buy on Kala after 'underwhelming' competitor data
05/11/20 Piper Sandler
Piper says Oyster Point 'highly likely' to get dry eye approval, superior label
03/30/20 Piper Sandler
Oyster Point ONSET-2 trial barely impacted by COVID-19, says Piper Sandler
OYST Oyster Point Pharma
$25.76 /

+0.67 (+2.67%)

  • 15
    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.